exciting chart, page-4

March 22nd is the date for the pre-NDA meeting.
This meeting has to precede the filing of the new drug
application which is targeted for the first half of
this calender year.
John Holiday Qrxparma chief executive told BiotechnologyNews.net that the company is on target for
that and to expect filing within four or five months.

Yes an exciting chart for an exciting company and product.

This post is not a recomendation to buy or sell QRX shares.
Consult a financial professional before making investment decisions.